Ms. Demeter is Research Operations Manager, Department of Psychiatry, Case Western Reserve University, Child and Adolescent Psychiatry, 11400 Euclid Ave., Triangle Building Suite #100, Cleveland, OH 44106; E-mail: [email protected]; Dr. Findling is Professor of Psychiatry and Pediatrics, Departments of Psychiatry and Pediatrics, Case Western Reserve University, and Director, Child and Adolescent Psychiatry, University Hospitals of Cleveland, Ohio.
Ms. Demeter has disclosed that she has no significant relationships with or financial interests in any commercial organizations pertaining to this educational activity.
Dr. Findling has disclosed that he is/was the recipient of grant/research support from and is/was a consultant to Abbott, AstraZeneca, Bristol-Myers Squibb, Celltech-Medeva, Forest, GlaxoSmithKline, Johnson & Johnson, Lilly, New River, Novartis, Otsuka, Pfizer, Shire, Solvay, and Wyeth; that he is/was a consultant for Sanofi-Aventis; and that he is/was a member of the speakers bureau for Shire.
The authors have disclosed that the use of fluoxetine is approved by the U.S. Food and Drug Administration for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) in pediatric patients. Fluvoxamine and sertraline are approved for the treatment of OCD in pediatric patients. All other listed antidepressants have not been approved for the treatment of MDD and OCD in children and adolescents.
